PRQR
ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (PRQR) has 5 SEC Form 4 filings (5 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Aug 3, 2026.
The most active filer is Chief Executive Officer de Boer Daniel Anton with 3 filings. Insiders have net bought $1.3M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Daniel Anton de Boer
- Employees:166
- HQ:Leiden, ZH, NL
- IPO:2014-09-18
Insider Buying
$1.3M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$181.2M
Price slightly stale
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Executive Officer | Purchase | 200,000 | $354K | Aug 3 | SEC ↗ | |
| Director | Purchase | 150,000 | $258K | Jul 21 | SEC ↗ | |
| Chief Executive Officer | Purchase | 150,000 | $261K | Jul 13 | SEC ↗ | |
de Boer Daniel AntonFirst filing | Chief Executive Officer | Purchase | 150,000 | $239K | Jul 8 | SEC ↗ |
Filius BartFirst filing | Director | Purchase | 150,000 | $231K | Jun 30 | SEC ↗ |
Related companies
ProQR Therapeutics N.V. is in the Healthcare sector.